HbA1c News and Research

RSS

Abbott receives CE Mark for ARCHITECT HbA1c test

Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.

9 May 2013

Nephropathy risk lowered by glucose, BP control in Type 1 diabetes

Individuals with Type 1 diabetes should keep good control of their blood sugar levels and blood pressure to reduce their risk for developing nephropathy, say researchers.

29 Apr 2013

Tree nuts consumption helps improve health

Three new studies involving tree nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts) were presented this week at the Experimental Biology Meeting in Boston, MA.

23 Apr 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

Study: Glycated hemoglobin levels of children with type 1 diabetes are correlated negatively with household income

Researchers at the University of Montreal have found that the glycated hemoglobin levels of children with type 1 diabetes followed at its affiliated Sainte-Justine Mother and Child University Hospital (CHU Sainte-Justine) is correlated linearly and negatively with household income.

4 Apr 2013

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Androgen deprivation therapy interferes with diabetes control

Androgen deprivation therapy for prostate cancer hampers glycemic control in men with diabetes, report researchers.

5 Mar 2013

Community health team improves diabetes control in Polynesian community

A team of community health workers has been able to improve control of Type 2 diabetes in a group of individuals from American Samoa – a medically underserved territory with a high prevalence of obesity, diabetes, and other cardiovascular risk factors, report researchers.

25 Feb 2013

Community health workers can help individuals better manage their diabetes

Newly published results from a randomized controlled clinical trial in the Pacific U.S. territory of American Samoa add clear evidence for the emerging idea that community health workers can meaningfully improve type 2 diabetes care in medically underserved communities.

12 Feb 2013

Diabetic peripheral neuropathy risk highlighted in children

US researchers call for clinical guidelines for detection of diabetic peripheral neuropathy in children after finding that a significant proportion of young patients are affected.

7 Feb 2013

Glycemic control low priority in diabetes CVD prevention

Maintaining glycemic control does not reduce the likelihood for cardiovascular disease leading to hospitalization in people with Type 2 diabetes, report US researchers.

4 Feb 2013

No added benefit from linagliptin in patients with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market for Medicinal Products (AMNOG) again showed that no added benefit of the drug over the appropriate comparator therapy (ACT) can be determined, because the pharmaceutical company has not submitted any relevant studies.

31 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Boehringer Ingelheim and Eli Lilly and Company today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor being studied for treatment of patients with Type 2 Diabetes (T2D).

9 Jan 2013

Intensive lifestyle intervention may increase likelihood of partial remission of type 2 diabetes

Among overweight adults, participation in an intensive lifestyle intervention (that included counseling sessions and targets to reduce caloric intake and increase physical activity) was associated with a greater likelihood of partial remission of type 2 diabetes, however the absolute remission rates were modest, according to a study in the December 19 issue of JAMA.

19 Dec 2012

Diabetes tests: an interview with Dr. Danielle Stowasser

Diabetes is a serious condition that causes high levels of glucose (a type of sugar) in the blood. There are three main types of diabetes: type 1 and type 2 diabetes, which are lifelong conditions, and gestational diabetes, which only occurs in women during pregnancy.

3 Dec 2012

Mindful eating reduces weight and blood sugar levels in adults with Type 2 diabetes

Eating mindfully, or consuming food in response to physical cues of hunger and fullness, is just as effective as adhering to nutrition-based guidelines in reducing weight and blood sugar levels in adults with Type 2 diabetes, a new study suggests.

9 Nov 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

HbA1c News and Research

Abbott receives CE Mark for ARCHITECT HbA1c test

Nephropathy risk lowered by glucose, BP control in Type 1 diabetes

Tree nuts consumption helps improve health

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Study: Glycated hemoglobin levels of children with type 1 diabetes are correlated negatively with household income

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

Androgen deprivation therapy interferes with diabetes control

Community health team improves diabetes control in Polynesian community

Community health workers can help individuals better manage their diabetes

Diabetic peripheral neuropathy risk highlighted in children

Glycemic control low priority in diabetes CVD prevention

No added benefit from linagliptin in patients with type 2 diabetes

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Intensive lifestyle intervention may increase likelihood of partial remission of type 2 diabetes

Diabetes tests: an interview with Dr. Danielle Stowasser

Mindful eating reduces weight and blood sugar levels in adults with Type 2 diabetes

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News